| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 生化机理 | TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
| 别名 | ; |
SB1317
SB1317 （订货以英文为准）
编号：S127924
CAS号：937270-47-8
分子式：C23H24N4O
分子量：372.46
| 产品名称 | SB1317 |
| 中文名称 | SB1317 |
| CAS号 | 937270-47-8 |
| 分子式（M.F.） | C23H24N4O |
| 分子量（M.W.） | 372.46 |
| 储存条件 | -20°C储存 |
搜索质检报告(COA)
搜索MSDS
相关产品
¥ 97.20
02053450-1个
¥ 60.00
60890B-25g
¥ 50.00
jx25528148-1盒
¥ 50.00
jx25528147-1盒
党沛 
